Study of Folate Receptor Alpha Expression in Women With Relapsed High-Grade Serous Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy

What this Trial Is About

Researchers are evaluating the presence of folate receptor alpha FR in adult women diagnosed with high-grade serous ovarian, fallopian tube, and primary peritoneal cancers. This observational study focuses on determining the prevalence of FR-positive status, defined as having at least 75% viable tumor cells with moderate to strong membrane staining, at different times such as initial diagnosis and relapse. The study follows specific assay interpretation guidelines to ensure consistent evaluation. Samples from eligible participants with these cancers will be analyzed retrospectively. The analysis includes archived surgical tissue samples collected from January 1st, 2016, to the study start date. These samples must be adequate for the Ventana folate receptor alpha FOLR1 RxDx assay as confirmed by site pathologists. Participants contribute by providing access to their archived tissue samples for analysis. Researchers will measure the FR-positive status within approximately six months. The study does not involve active treatment but focuses on understanding the receptors prevalence. The total participation involves retrospective sample analysis without additional procedures or interventions.

A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy